Exscientia, the Oxford-based pioneer in artificial intelligence (AI)-based drug development, has advanced the first of three candidates planned for first-in-human studies this year—an immunology and inflammation (I&I) small molecule designed by the company and licensed to Bristol…
Source: www.genengnews.com – Read more
